SG11201901991QA - Methods of detecting per cell pd-l1 expression and uses thereof - Google Patents
- ️Mon Apr 29 2019
SG11201901991QA - Methods of detecting per cell pd-l1 expression and uses thereof - Google Patents
Methods of detecting per cell pd-l1 expression and uses thereofInfo
-
Publication number
- SG11201901991QA SG11201901991QA SG11201901991QA SG11201901991QA SG11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA SG 11201901991Q A SG11201901991Q A SG 11201901991QA Authority
- SG
- Singapore Prior art keywords
- international
- methods
- expression
- california
- per cell Prior art date
- 2016-09-06
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N2015/1006—Investigating individual particles for cytology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N2015/1486—Counting the particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 3E1 0 011101111110111111 OHRE III OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2018/048936 Al 15 March 2018 (15.03.2018) WIP0 I PCT — (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) (71) International Patent Classification: (74) Agent: FIELD, Bret E.; 201 Redwood Shores Parkway, G01N 1/30 (2006.01) G01N 33/574 (2006.01) Suite 200, Redwood City, California 94065 (US). G01N 33/483 (2006.01) G01N 15/14 (2006.01) (81) Designated States (unless otherwise indicated, for every International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/US2017/050322 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, International Filing Date: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 06 September 2017 (06.09.2017) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, Publication Language: English MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Priority Data: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/384,037 06 September 2016 (06.09.2016) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Applicant: INCELLDX, INC. [US/US]; 1700 El Camino (84) Designated States (unless otherwise indicated, for every Real, Menlo Park, California 94027 (US). kind of regional protection available): ARIPO (BW, GH, Inventors; and GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Applicants: PATTERSON, Bruce K. [US/US]; 274 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Mosher Way, Palo Alto, California 94304 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, CHARGIN, Amanda Noel [US/US]; 11 Jackson Street, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, San Jose, California 95112 (US). SHULTS, Keith TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, [US/US]; 9825 Sam Donald Road, Nolensville, Tennessee KM, ML, MR, NE, SN, TD, TG). 37135 (US). = = = Title: METHODS OF , — ..-_-, (54) DETECTING PER CELL PD-L1 EXPRESSION AND USES THEREOF , of neoplasia cells. to detect whether addition, kits that find = = C , pos(77 20 %) PD-L1 pos(0.21 %) = = = = _ = = : Methods are of the methods include cytometrically assaying a labeled cell suspension neoplastic cell that expresses PD-L1 above a predetermined threshold in practicing the subject methods are also provided. -- -- GO Aspects 1 i 0 2 10' 10• 10 5 10 7 10' APC-A FIG, 1 provided for detecting the per cell programmed 1 . Q - 10 4 10 5 1 0 5 10 7 APC-A -death ligand 1 (PD-L1) expression to quantify per cell PD-L 1 expression is present in the neoplasia sample. In _ Il .4 M tz. co ii- © (57) ,-1 a 0 use ei O [Continued on next page] WO 2018/048936 Al MIDEDIMOMMIDEFIEHVIVEHEMERMOVOIS Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662384037P | 2016-09-06 | 2016-09-06 | |
PCT/US2017/050322 WO2018048936A1 (en) | 2016-09-06 | 2017-09-06 | Methods of detecting per cell pd-l1 expression and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901991QA true SG11201901991QA (en) | 2019-04-29 |
Family
ID=61561676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901991QA SG11201901991QA (en) | 2016-09-06 | 2017-09-06 | Methods of detecting per cell pd-l1 expression and uses thereof |
Country Status (11)
Country | Link |
---|---|
US (1) | US10782298B2 (en) |
EP (1) | EP3510378A4 (en) |
JP (2) | JP2019535001A (en) |
CN (2) | CN109906367A (en) |
BR (1) | BR112019004470A2 (en) |
CA (1) | CA3036278A1 (en) |
CR (1) | CR20190172A (en) |
IL (1) | IL265175A (en) |
MX (1) | MX2019002578A (en) |
SG (1) | SG11201901991QA (en) |
WO (2) | WO2018048936A1 (en) |
Families Citing this family (9)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019004470A2 (en) * | 2016-09-06 | 2019-09-03 | Incelldx Inc | methods for detecting pd-l1 expression by cells and its uses |
US11726089B2 (en) | 2016-09-06 | 2023-08-15 | Incelldx, Inc. | Methods of assaying neoplastic and neoplasia-related cells and uses thereof |
CN112740042A (en) * | 2018-09-20 | 2021-04-30 | 文塔纳医疗系统公司 | Based on size gating to analyze flow cytometry data |
CN113330310A (en) * | 2018-11-09 | 2021-08-31 | 皮埃里亚生物科学有限责任公司 | Methods and compositions for determining tumor microenvironment composition |
WO2020168244A1 (en) * | 2019-02-15 | 2020-08-20 | Incelldx, Inc. | Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein |
CN110142068B (en) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | Kit and method for detecting epithelial and mesenchymal mixed circulating tumor cells |
CN111735955A (en) * | 2020-04-20 | 2020-10-02 | 山东省肿瘤防治研究院(山东省肿瘤医院) | Immunofluorescence detection method for PD-L1 expression on peripheral blood circulation tumor cells of hepatocellular carcinoma patient |
CA3211402A1 (en) * | 2021-03-10 | 2022-09-15 | Moshe ELKABETS | Reporter cells expressing chimeric polypeptides for use in determining presence and or activity of immune checkpoint molecules |
CN113358872B (en) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Marker panel and system for evaluating the efficacy of tumor immunotherapy |
Family Cites Families (14)
* Cited by examiner, † Cited by third partyPublication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003300676A1 (en) * | 2003-01-03 | 2004-07-29 | Aurelium Biopharma Inc. | Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
EP3428191B1 (en) * | 2004-10-06 | 2024-12-18 | Mayo Foundation for Medical Education and Research | B7-h1 and pd-1 in treatment of renal cell carcinoma |
WO2007136026A1 (en) * | 2006-05-19 | 2007-11-29 | Bml, Inc. | Method of quantitative determination of antigen protein and quantitative determination kit therefor |
EP2850102A1 (en) * | 2012-05-15 | 2015-03-25 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
AR095363A1 (en) | 2013-03-15 | 2015-10-14 | Genentech Inc | BIOMARKERS AND METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO PD-1 AND PD-L1 |
KR102276644B1 (en) * | 2013-09-04 | 2021-07-13 | 브리스톨-마이어스 스큅 컴퍼니 | Compounds useful as immunomodulators |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
EP3060919A4 (en) * | 2013-10-25 | 2018-02-14 | Nodality, Inc. | Methods and compositions for immunomodulation |
JP6355154B2 (en) * | 2014-04-03 | 2018-07-11 | 公益財団法人ヒューマンサイエンス振興財団 | Diagnosis assistance method |
CN107001478B (en) * | 2014-10-14 | 2022-01-11 | 诺华股份有限公司 | Antibody molecules against PD-L1 and uses thereof |
US20170242016A1 (en) | 2014-10-15 | 2017-08-24 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
CN108026533B (en) * | 2015-09-01 | 2021-08-17 | 中央研究院 | Antagonistic PDL1 aptamer and its application in cancer therapy |
HUE048265T2 (en) | 2015-10-27 | 2020-08-28 | Pharmassist Ltd | Method for quantification of PD-L1 |
BR112019004470A2 (en) | 2016-09-06 | 2019-09-03 | Incelldx Inc | methods for detecting pd-l1 expression by cells and its uses |
-
2017
- 2017-09-06 BR BR112019004470A patent/BR112019004470A2/en not_active Application Discontinuation
- 2017-09-06 EP EP17849473.8A patent/EP3510378A4/en active Pending
- 2017-09-06 JP JP2019512878A patent/JP2019535001A/en not_active Ceased
- 2017-09-06 SG SG11201901991QA patent/SG11201901991QA/en unknown
- 2017-09-06 WO PCT/US2017/050322 patent/WO2018048936A1/en unknown
- 2017-09-06 CN CN201780063086.4A patent/CN109906367A/en active Pending
- 2017-09-06 CR CR20190172A patent/CR20190172A/en unknown
- 2017-09-06 CA CA3036278A patent/CA3036278A1/en not_active Abandoned
- 2017-09-06 MX MX2019002578A patent/MX2019002578A/en unknown
-
2018
- 2018-01-03 US US15/861,352 patent/US10782298B2/en active Active
-
2019
- 2019-01-02 WO PCT/US2019/012074 patent/WO2019136082A1/en active Application Filing
- 2019-01-02 CN CN201980016405.5A patent/CN112088309A/en active Pending
- 2019-03-05 IL IL265175A patent/IL265175A/en unknown
-
2022
- 2022-06-14 JP JP2022096028A patent/JP2022133307A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2019002578A (en) | 2019-09-18 |
IL265175A (en) | 2019-05-30 |
CN112088309A (en) | 2020-12-15 |
CR20190172A (en) | 2019-06-13 |
CN109906367A (en) | 2019-06-18 |
CA3036278A1 (en) | 2018-03-15 |
BR112019004470A2 (en) | 2019-09-03 |
WO2018048936A1 (en) | 2018-03-15 |
US10782298B2 (en) | 2020-09-22 |
US20180136214A1 (en) | 2018-05-17 |
EP3510378A1 (en) | 2019-07-17 |
WO2019136082A1 (en) | 2019-07-11 |
JP2019535001A (en) | 2019-12-05 |
JP2022133307A (en) | 2022-09-13 |
EP3510378A4 (en) | 2020-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901991QA (en) | 2019-04-29 | Methods of detecting per cell pd-l1 expression and uses thereof |
SG11201908719QA (en) | 2019-10-30 | Biomarkers and car t cell therapies with enhanced efficacy |
SG11201901834WA (en) | 2019-03-28 | Micrornas as biomarkers for endometriosis |
SG11201811740WA (en) | 2019-09-27 | Systems and methods for identifying risky driving behavior |
SG11201810221YA (en) | 2018-12-28 | Fidelity estimation for quantum computing systems |
SG11201910019PA (en) | 2019-11-28 | Microorganisms and methods for producing cannabinoids and cannabinoid derivatives |
SG11201810611YA (en) | 2018-12-28 | Coumarin compounds and their uses as fluorescent labels |
SG11201908787WA (en) | 2019-10-30 | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
SG11201808022WA (en) | 2018-10-30 | Selection and cloning of t lymphocytes in a microfluidic device |
SG11201808196UA (en) | 2018-10-30 | Neoantigens and methods of their use |
SG11201803983UA (en) | 2018-06-28 | Transformable tagging compositions, methods, and processes incorporating same |
SG11201810633WA (en) | 2018-12-28 | New fluorescent dyes and their uses as biomarkers |
SG11201810887UA (en) | 2019-01-30 | Baff-r targeted chimeric antigen receptor-modified t-cells and uses thereof |
SG11201901577SA (en) | 2019-05-30 | Method and system for fast tracking navigation of blockchains via data manipulation |
SG11201809913PA (en) | 2018-12-28 | Methods for detecting target nucleic acids in a sample |
SG11201900772YA (en) | 2019-02-27 | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors |
SG11201903771XA (en) | 2019-05-30 | Binding molecules specific for asct2 and uses thereof |
SG11201804144UA (en) | 2018-06-28 | High-throughput imaging-based methods for predicting cell-type-specific toxicity of xenobiotics with diverse chemical structures |
SG11201908743SA (en) | 2019-10-30 | Methods and compositions for modulation of immune cells |
SG11201804360XA (en) | 2018-06-28 | Mat2a inhibitors for treating mtap null cancer |
SG11201811550XA (en) | 2019-02-27 | Demand prediction for time-expiring inventory |
SG11201806284TA (en) | 2018-08-30 | Low pressure separator having an internal divider and uses therefor |
SG11201811329UA (en) | 2019-01-30 | Spheroids including biologically-relevant materials and related methods |
SG11201907764PA (en) | 2019-09-27 | Methods for screening infections |
SG11201805170XA (en) | 2018-07-30 | Cellular glycosaminoglycan compositions and methods of making and using |